How to avoid risks in IPR protection and improve awareness as well as innovation ability? ---Find out by attending the 2nd Pharma and Biotech Patent Conference 2010!
China is ready to move to the next stage of its economic evolution, as an innovation and knowledge based economy. IP management has become the most important protection tool for R&D. With 2010 being the key year to implement the national intellectual property strategy of China, pharmaceutical and biotech companies in particular now focus on obtaining as well as enforcing patents. Continuing last year’s success, 2nd Pharma and Biotech Patent Conference 2010 will come back on 26th & 27th August, 2010 in Pullman Shanghai Skyway Hotel.
Our conference will provide you with what you need to know about patents in pharma and biotech industry through variety of case studies, panel discussions, focused mini-workshops and intense networking. By attending you will:
(1) Review the US/ EU patent Law amendments and comparison with the Chinese patent law relevant to pharmaceutical and biotech industries,
(2) Identify the overall strategies in patent prosecution, maximizing legal protection of IP assets
(3) Develop knowledge facing litigation concerning IP infringement and violations from the judicial perspective with case studies.
(4) Gain tactical maneuvers in pharmaceutical patent lifecycle management facing the challenges of promising generic products market
(5) Set up the IP protection framework and strategy in the traditional Chinese medicine
2nd Pharma and Biotech Patent Conference 2010 enjoys the support of prominent government departments & international leading pharmaceutical companies working in the field of patent protection and lifecycle management.
We are honored to have the following eminent speakers on board to share their knowledge, experience and views with our participants.
Qingkui Zhang, Director General, the Pharmaceutical and Biological Examination Department, SIPO
Xiaoting Song, Chief of Research Section, Professor, Tongji University, Law School
Director, Shanghai Intellectual Property Research Center of Traditional Chinese Medicine
Prof. Zhipei Jiang, Chief Justice of IPR Tribunal, PRC Supreme People’s Court (Retired)
Dr. Hubert Witte, Head of Patent Department, Roche
Peter L. Dolan, Head of India, China, Japan & Asia Pacific Region Patents, Sanofi-aventis
David Shen, Asia Regional IP Counsel, Eli Lilly
Alex Liu, Senior Patent Counsel, Bayer (China) Limited
Etc
Also, thanks to our sponsors Kenyon & Kenyon LLP, Finnegan Henderson, Farabow, Garrett, Winston & Strawn LLP, Beijing Sanyou Intellectual Property Agency and NTD Patent and Trademark Agency Limited, we are expecting senior management and legal professionals from intellectual property, licensing as well as R&D functions from pharmaceutical Companies, biotech companies, IP agency to join our 2nd Pharma and Biotech Patent Conference 2010 in Shanghai.
For further details and registrations please contact Molly Jiang at:
Tel: 86 21-5228 6122
LexisNexis
LexisNexis® is a leading provider of comprehensive information and business solutions, including its flagship Web-based Lexis® and Nexis® research services, to a wide range of professionals in the legal, risk management, corporate, government, law enforcement, accounting and academic markets.
LexisNexis established office in Hong Kong in 1994, and currently it has set up offices in Beijing, Shanghai and Guangzhou in the mainland. Adhering to its conventions, LexisNexis has been making efforts to provide superior products and services in the legal and commercial sectors and to contribute to the development of China's legal undertakings.
Pharma Legal 2010-08-11_MKT_ChinaIP.pdf
